



Kyma Capital Limited

Idorsia Ltd (Bloomberg: IDIA SW)

**Kyma Addresses holders of Idorsia's 2025 Notes (CH0426820350)**

29 November 2024

London, UK – Kyma Capital Limited ("Kyma"), a significant holder of Idorsia's 2025 Notes, wishes to communicate the following to all noteholders:

**Support for Idorsia and Aprocitentan (TRYVIO™).** Kyma applauds Idorsia's recent developments, particularly the agreement announced on November 27, 2024, regarding aprocitentan (TRYVIO™). Kyma remains enthusiastic about the commercial potential of aprocitentan.

**Facilitation of Maturity Extension.** Earlier this year, Kyma played a pivotal role in extending the maturity of Idorsia's 2024 Notes to January 2025, providing critical time for the company to pursue an optimal transaction for aprocitentan and other strategic objectives that have since progressed.

**Call to Noteholders.** Kyma encourages all 2025 noteholders to reach out for information. We aim to ensure all holders are informed and prepared for forthcoming discussions. Kyma has not retained a financial advisor at this stage.

Noteholders seeking further details or wishing to discuss their position are encouraged to contact **Renata Machado**, Chief Operating Officer.

**About Kyma Capital**

Kyma Capital Limited is a London-based investment manager authorized by the Financial Conduct Authority. It manages Kyma Capital Opportunities Fund, an all-weather, event-driven fund investing in public and private securities.

For further enquiries, please contact:

Renata Machado  
Chief Operating Officer  
[rmachado@kymacapital.com](mailto:rmachado@kymacapital.com)